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Abstract
Purpose Disseminated tumor cells (DTCs) in the BM of breast cancer patients predict early disease relapse, but the molecular 
heterogeneity of these cells is less well characterized. Expression of a 46-gene panel was used to detect DTCs and classify 
patient BM samples to determine whether a composite set of biomarkers could better predict metastatic relapse.
Methods Using a high-throughput qRT-PCR assay platform, BM specimens collected from 70 breast cancer patients prior 
to neoadjuvant therapy were analyzed for the expression of 46 gene transcripts. Gene expression was scored positive (detect-
able) relative to a reference pool of 16 healthy female control BM specimens. To validate findings from a subset of 28 triple-
negative breast cancer (TNBC) patients in the initial 70 patient cohort, an independent set of pre-therapeutic BM specimens 
from 16 TNBC patients was analyzed.
Results Expression of each of the 46 gene transcripts was highly variable between patients. Individual gene expression 
was detected in 0–84% of BM specimens analyzed and all but two patient BM specimens expressed at least one transcript. 
Among a subset of 28 patients with TNBC, positivity of one or more of eight transcripts correlated with time to distant 
relapse (p = 0.03). In an independent set of 16 triple-negative patient BM samples, detection of five of these same eight gene 
transcripts also correlated with time to distant relapse (p = 0.03) with a positive predictive value of 89%.
Conclusions We identified a set of gene transcripts whose detection in the BM of TNBC patients, prior to any treatment 
intervention, predicts time to first distant relapse, thus identifying a TNBC patient population which requires additional 
treatment intervention. Because these genes are presumably expressed in populations of DTCs and many encode proteins 
that are known therapeutic targets (e.g., ERBB2), these results also suggest a potential approach for targeted DTC therapy 
to mitigate distant metastases in TNBC.
Keywords Triple-negative breast cancer · Disseminated tumor cells · Metastasis · Gene expression · Targeted therapy
Introduction
Metastasis is the most significant contributor to mortality in 
breast cancer patients. Many preclinical studies suggest that 
only a small, unique subset of cells within a primary tumor Electronic supplementary material The online version of this 
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possesses metastatic potential and that the molecular pheno-
type of these cells may evolve as they transition outside of 
the primary tumor and progress to metastatic foci [1–3]. To 
develop new therapeutic interventions that will effectively 
monitor and prevent overt distant disease development, it is 
essential to identify and target these intermediary cells in 
the metastatic process since these cells likely have biological 
behavior and therapeutic vulnerabilities which differ from 
the corresponding primary tumor.
Disseminated tumor cells (DTCs) can be detected in the 
bone marrow (BM) of 30–40% of early-stage breast can-
cer patients by immunocytochemical (ICC) staining of 
cytokeratins. Several large multi-institutional clinical stud-
ies have documented that BM DTCs are an independent 
prognostic factor for patients with stage I–III disease [4–6]. 
While the detection of BM DTCs may simply be a surrogate 
marker of body-wide tumor cell dissemination, an attrac-
tive alternative hypothesis is that BM serves as a specific 
reservoir that allows DTCs to adapt and disseminate to other 
organs after some period of latency [7].
DTCs are molecularly heterogeneous, genetically distinct 
from their originating primary tumor, and likely have vary-
ing metastatic potential [8–10]. They can persist for years 
and remain a predictor of disease recurrence [11]. Patients 
with detectable DTCs in their BM after chemotherapy have 
a particularly poor prognosis, suggesting that conventional 
chemotherapy does not eliminate all DTCs and that those 
subpopulations which survive cytotoxic chemotherapy have 
a high metastatic potential and may exhibit a stem cell-like 
chemotherapy-resistant phenotype [12].
Although DTCs may be tenfold more abundant than cir-
culating tumor cells (CTCs) found in the peripheral blood, 
they are still exceedingly rare (1–10 DTCs per million 
mononuclear immunocytes) which makes their individual 
molecular characterization difficult [13]. Current methods to 
detect BM DTCs by ICC or single-gene expression biomark-
ers are technically demanding and lack sufficient sensitivity, 
specificity, and clinical utility for use in routine clinical prac-
tice, particularly where serial monitoring may be required 
[14, 15]. Therefore, the development of new analytical 
techniques and biomarkers for the detection, classification, 
and, in particular, therapeutic targeting of BM DTCs could 
identify patients at high risk for the development of distant 
metastatic disease and mitigate its progression.
We previously developed a strategy for identifying genes 
whose expression is associated with BM DTCs in breast 
cancer patients [16, 17] and now describe a sensitive, mul-
tiplex gene expression assay platform (Fluidigm Biomark 
HD) for their detection. The current study demonstrates the 
potential clinical utility of a 46-gene expression panel that 
detects and classifies BM DTCs in breast cancer patients. 
More specifically, in ‘triple-negative’ breast cancer (lacking 
expression of estrogen receptor and Her2, TNBC) patients, 
expression of an eight-gene subset of this panel correlates 
with time to distant metastatic relapse in two independent 
cohorts of patients. Since many of these genes and their 
corresponding proteins are actionable therapeutic targets, 
in addition to risk-stratification, this also suggests a new 
paradigm for the detection and targeted elimination of BM 
DTCs based upon specific and unique molecular markers, 
to prevent metastatic progression.
Materials and methods
Patients
Under an IRB-approved protocol (# 201309087) with 
informed consent, anonymized control BM specimens were 
collected from female volunteers with no current or past 
history of cancer, who were undergoing hip replacement 
surgery. BM specimens for the test clinical cohort were col-
lected from an ongoing IRB-approved BM and tissue bank-
ing protocol from clinical stage II/III breast cancer patients 
at our institution which began in 2011 (IRB # 201101961). 
BM specimens for the validation cohort of clinical stage 
II/III TNBC patients were obtained from a retrospective 
collection banked in the context of a previous clinical trial 
evaluating the use of zoledronic acid to prevent growth and 
survival of DTCs (NCT00242203) [18]. Only patients in the 
control arm, not receiving zoledronic acid, were evaluated 
in this study. Patients received standard chemotherapy with 
an anthracycline, cyclophosphamide and a taxane. Patients 
with Her2-positive tumors received Trastuzumab and estro-
gen receptor (ER)-positive patients received adjuvant hor-
monal therapy. All patient BM aspirates used for the current 
study were collected prior to the initiation of any therapeutic 
interventions.
BM aspiration, processing, and RNA isolation
For all breast cancer cases, 20 ml of BM was collected from 
both the right and left anterior iliac crests, subjected to 
hypotonic RBC lysis, washing, and nucleated cell counting 
within 2 h from the time of collection. For controls, BM 
was harvested unilaterally. For whole BM analysis, 5 × 106 
nucleated cells were pelleted and immediately snap frozen 
for subsequent RNA isolation. All RNA isolations were per-
formed from snap-frozen cell pellets using Trizol reagent 
(Invitrogen). RNA was quantified and qualitatively assessed 
by A260, A280, and A230 readings using a Nanodrop spec-
trophotometer, and further qualified by RIN score using 
an Agilent bioanalyzer. For breast cancer samples, 500 ng 
from each left and right BM sample was pooled for a single 
sample analysis from each patient in the test cohort. In the 
validation cohort, left and right BM samples were analyzed 
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independently and gene expression positivity in either one 
of the sample pairs was considered positive for the patient.
Multiplexed qRT‑PCR
Quantitative PCR was performed using a microfluidic-based 
PCR system with 96.96 Dynamic Arrays (Fluidigm Corp. 
San Francisco, CA). For each BM sample, cDNA was syn-
thesized from 50 ng of total RNA using Life Technologies 
High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA). Each cDNA was then sub-
jected to specific target amplification (STA) using TaqMan 
PreAmp Mastermix (Applied Biosystems, Foster City, CA). 
The samples underwent 14 rounds of amplification in the 
STA process. The cycling program consisted of 10 min at 
95 °C followed by 14 cycles of 95 °C for 15 s and then 60 °C 
for 1 min. Each completed STA reaction was diluted 1:4 
in low-EDTA DNA suspension buffer for qPCR. Reactions 
were prepared by combining samples with TaqMan Univer-
sal PCR Master Mix (Applied Biosystems) and 20× Gene 
Expression Sample Loading Reagent (Fluidigm Corp.). The 
assay mixtures contained 9 µM of each primer and 2 µM of 
the probe in Dynamic Array Assay Loading Reagent (Flui-
digm Corp). Primer and probe sequences for each transcript 
used for the STA and PCRs are listed in Supplemental 
Table 1. Sample and assay mixtures were loaded into the 
primed 96.96 Dynamic Array chip and the NanoFlex-4 Inte-
grated Fluidic Circuit Controller was used for the distribu-
tion of the sample and assay mixture. The loaded Dynamic 
Array was run on a BioMark™ Reverse-Transcription-PCR 
System. The qPCR program was as follows: 50 °C for 2 min, 
95 °C for 2 min, 40 cycles of 95 °C for 15 s and 60 °C for 
1 min. All PCRs were run in duplicate.
Data and statistical analysis
Each of the 9216 PCRs in the array produced a raw PCR 
cycle threshold (CT) value which was used for subsequent 
calculation. Duplicate PCRs which deviated by more than 
1 CT were discarded and marked as ‘failed’. Expression of 
each of the 46 target genes in each control sample was cal-
culated using the ddCT method, with expression of GUSB 
used as the normalizer for each sample. Since the expres-
sion of most target genes (by definition) was not detected 
in control BM samples, a baseline of 27 cycles was defined 
as ‘not detected’. The average and standard deviation (SD) 
of expression of each gene across all control samples were 
calculated. This process was repeated for each of the patient 
samples. When the relative expression level of a gene in a 
patient sample exceeded 3 SD above the mean of the con-
trol samples, expression of that gene was scored as posi-
tive. Hierarchical clustering and principal component visu-
alizations were performed using binary data (‘positive’ vs. 
‘negative’) and Partek Genomics Suite. Time to distant 
relapse was defined as the time from diagnosis to the time 
of first-detected distant recurrence. Kaplan–Meier plots were 
generated with Graph Pad Prism.
Results
Molecular profiling of BM samples
To better understand the clinical relevance of a previously 
identified DTC-associated gene expression panel, which 
comprised a set of 46 genes frequently expressed by breast 
cancer cells but with very limited or absent expression in 
healthy BM samples [17], we evaluated expression in the 
pre-therapeutic BM of 70 clinical stage II/III breast cancer 
patients using high-density array-based qRT-PCR. Twenty 
of the 70 patients in this cohort (29%) developed distant 
metastatic relapse (Table 1). The largest percentage of recur-
rences was observed in the TNBC patients (42%) and the 
ER+/Her2+ (45%). Among the 70 patients, 69 had detect-
able expression of one or more of the DTC panel genes. 
Table 1  Clinical characteristics 70 patients evaluated for the expres-
sion of 46 genes
Recurrent (n = 20) Non-
recurrent 
(n = 50)
Mean age (years) 49 50
Race
 Caucasian 13 32
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The patient specimen lacking in expression of any of the 
genes was Her2 positive and did not develop metastases. 
The total number of genes expressed ranged from 1 to 23 in 
each patient’s BM but was unrelated to risk or time to distant 
disease relapse (data not shown).
Among individual genes, 12 of the 46 genes (CLDN4, 
EGFR, ESR1, FOXA1, HES1, KRT17, KRT19, LOXL2, 
MAGEA3, MAPT, NPY1R and PTEN) in the panel were not 
detected in any of the patient BM samples. In some cases, 
such as KRT19, gene expression was detectable but levels 
were not above those detected in the BM of the reference 
female heathy controls, supporting previous studies that 
show this marker lacks specificity [14]. The remaining 
genes were expressed in 1–23 patient BM samples. Indi-
vidually, the detection of several genes was associated pri-
mary tumor ER status (GRB7, SCUBE2, LAMB1, WNT5A, 
EPCAM), lymph node status at presentation (STEAP 1), 
and, in particular, distant metastatic relapse (MLPH, 
AGXT2L1), although none of these associations was sig-
nificant after correction for multiple comparisons (Sup-
plemental Table 2). Of note, EpCAM, which is frequently 
used as a target for enrichment for DTCs was expressed in 
8% of the samples. As shown in Fig. 1, the overall expres-
sion pattern of the 46 genes was extremely heterogeneous 
and no subsets of genes demonstrated coordinated expres-
sion between patient BM specimens.
Fig. 1  Hierarchical cluster visualization of 34 expressed gene tran-
scripts, across 70 BM samples from breast cancer patients. Patients 
with metastatic relapse (M), patients with triple-negative disease 
(TN), and patients with HER2-positive primary tumors are shown 
in the top annotation tracks. Patients with ERBB2-positive BM sam-
ples and HER2-negative primary tumors, who experienced metastatic 
relapse are highlighted in red
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BM gene expression of actionable biomarkers
Because several of the genes in the panel were purposely 
chosen for their targetable therapeutic relevance (e.g., 
ERBB2, PDGFRB, STEAP1, WNT5A), it was particularly 
interesting to note recurrent, detectable expression of these 
genes in many patient BM samples. For example, as previ-
ously noted by others [19, 20], we detected ERBB2 expres-
sion in four patient BM samples, although the corresponding 
primary tumor was ERBB2 negative (Fig. 1). Although the 
presence of ErbB2 expression in the BM of ErbB2 (Her2)-
positive patients had no impact on progression to distant 
metastases, as shown in Fig. 2, patients with ErbB2-negative 
tumors who were not treated with Trastuzumab had a much 
shorter time to metastatic recurrence when there was detect-
able erbB2 expression in BM (HR 3.0, 95% CI 0.85–10.62). 
Although the number of such patients in this analysis was 
small, it suggests the utility of biomarker-directed targeted 
therapy based on BM DTC molecular profiling in pre-meta-
static patients, independent of primary tumor status. In fact, 
this is a paradigm that has been now tested for BM erbB2 
expression as a predictive marker in a clinical trial setting 
(NCT01779050), currently in follow-up.
Prognostic utility of BM gene expression
As expected, detectable BM gene expression was not 
strongly prognostic based upon single-gene biomark-
ers (Supplemental Table 2). We, therefore, attempted to 
define subsets of genes whose combined expression in 
pre-therapeutic BM samples could collectively identify 
those patients at highest risk for distant metastatic relapse. 
No combination of gene expression was able to distinguish 
outcomes among all 70 patients. Therefore, to address a 
more clinically homogenous cohort with frequently aggres-
sive disease, we focused specifically on a subset of 28 
patients with ‘triple-negative’ (ER negative, progesterone 
receptor negative, Her2 negative, TNBC) primary tumors. 
After optimizing a minimal combination of genes whose 
expression produced the greatest sensitivity and specificity 
for distant disease recurrence, we identified a panel of eight 
genes—KRT5, SNAI2, PTCH1, CAV1, SMO, ERBB2, PDG-
FRB, and SRC. TNBC patients whose BM had detectable 
levels of at least one of these eight genes had significantly 
shorter time to distant metastatic relapse than patients whose 
BM had no detectable expression of any of these genes 
(p = .0319) (Fig. 3a). Additionally, those patients whose 
pre-therapeutic BM panel was positive for at least one gene 
never experienced a complete pathological response to neo-
adjuvant therapy, as compared to those patients who had 
no detectable BM gene panel expression prior to treatment 
(Fig. 4a). Among these eight genes, the specific combination 
and number of detectable transcripts itself were unrelated to 
outcome. This same eight-gene expression panel was also 
not prognostic for time to progression in patients with ER-
positive or Her2-positive tumors. Although the total number 
of patients and percent recurrence was limiting in this subset 
analysis, this result suggests that the biomarker panel may 
be specific for predicting progressive disease only in triple-
negative patients.
Fig. 2  Kaplan–Meier analysis 
of time to metastatic relapse for 
70-patient cohort, stratified by 
ERBB2 detection in BM and 
whether the patient received 
Trastuzumab therapy for a 
corresponding ERBB2-positive 
primary tumor
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Because of the obvious ‘over-fitting’ of the gene expres-
sion panel in the first sample set, we next evaluated the 
prognostic significance of the same 8-gene BM expression 
panel in a second, independent cohort of 16 patients with 
TNBC (Table 2). Pre-therapeutic BM samples from these 
patients were obtained in the context of a therapeutic trial 
of zoledronic acid administration [18]. Although the eight-
gene expression panel lacked sufficient specificity to fully 
predict distant metastatic relapse in this cohort using the 
same criteria, a set of five of the same eight genes (ERBB2, 
PDGFRB, PTCH1, SMO, and SRC) analyzed in this cohort 
Fig. 3  Kaplan–Meier analysis of time to distant metastatic relapse for TNBC patients based upon gene expression. a Initial 28 patients using the 
8-gene expression panel; b independent, validation cohort of 16 patients using the 5-gene expression subpanel
Fig. 4  Distribution of initial 70-patient test cohort, based on primary 
tumor molecular phenotype, 8-gene expression panel result at initial 
diagnosis, subsequent pathological response to neoadjuvant therapy, 
and eventual progression to distant metastasis. Correlation between 
gene expression panel result and residual disease is shown (Fisher’s 
exact test). RD residual disease, pCR pathological complete response, 
M distant metastatic disease development
Table 2  Clinical characteristics 16 TNBC patients (validation cohort) 
evaluated for 8-gene BM DTC signature
Recurrent (n = 10) Non-
recurrent 
(n = 6)
Mean age (years) 44 53
Race
 Caucasian 4 4
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also significantly stratified those patients into low and high 
risks for distant metastatic relapse (p = .0314, Fig. 3b).
Discussion
The presence of DTCs in the BM of early-stage breast can-
cer patients has demonstrated prognostic significance [4–6]. 
Most assays employ ICC detection of epithelial antigens 
[14] or PCR-based gene expression [15] but have not been 
adopted as standard-of-care diagnostics because BM aspira-
tions are not routinely performed on breast cancer patients, 
current detection assays are technically complex or expen-
sive, and results are not immediately actionable in most 
breast cancer patients. The present study was designed to 
address whether multi-marker detection of DTCs and molec-
ular classification of BM could result in a more specific, 
sensitive, robust, and actionable assay.
The 46-gene expression panel described in this report 
was originally derived from a series of microarray-based 
gene expression experiments to define ‘DTC-specific’ gene 
expression [16]. This gene list was refined based upon absent 
expression in panels of age-matched BM samples from 
healthy female volunteers and detectable expression in a 
number of breast cancer cell lines and primary tumors [17]. 
The gene list was also purposefully biased toward selection 
of genes which could serve as potential therapeutic targets. 
In the absence of single-cell expression analyses, it is not 
definitively known whether the expression of each gene orig-
inates from tumor cells themselves or reactive, rare BM cell 
populations, specifically in patients with micrometastatic 
disease. The precise cellular origin of gene expression is 
an interesting biological question that is the topic of ongo-
ing studies using single-cell expression profiling and in situ 
gene expression analyses. However, preliminary data from 
our laboratory, using RNA in situ hybridization, confirm the 
expression of ERBB2 and STEAP1 by DTCs. Several other 
previously defined DTC gene expression biomarkers [21], 
particularly related to ‘stem-cellness’, were not included in 
this 46-gene panel, primarily because they are frequently 
detected in the BM of non-breast cancer patients and lacked 
the stringent specificity required for the assay.
It was surprising to find both the high frequency and great 
heterogeneity of gene expression in the BM samples from 
this patient cohort. We found the expression of at least one 
of the 46 genes was detected in all but one Her2-positive 
patient, whereas the traditional detection of DTCs by ICC 
methods averages 20–30% in similarly staged breast cancer 
patients [5, 6]. One explanation for this discrepancy may be 
that traditional immunocytochemistry methods only measure 
epithelial antigens such as cytokeratin and EpCAM, which 
can be frequently downregulated in metastatic tumor cells 
or cells that revert to a ‘stem cell-like’ phenotype [14, 15]. 
For example, in our BM cohort, EpCAM expression was 
detected in only 8% of patient BM and Keratin19 was not 
significantly expressed in any of the specimens. In fact, the 
prevalence of BM DTCs in stage II/III breast cancer may 
be much higher when a broader gene expression-based bio-
marker assessment is considered, even if DTCs detected by 
this approach do not all have uniform metastatic potential. 
This would be consistent with the continued release of thou-
sands of cancer cells from the primary tumor.
Our initial hypothesis was that a set of identifiable genes 
would be detectable in all DTCs regardless of tumor subtype 
which allows them to migrate and survive in the BM. How-
ever, the overall heterogeneity of gene expression observed 
was not associated with sample clustering based upon pat-
terns of gene expression and there was no significant asso-
ciation with ER status or tumor stage. This could in part be 
due to technical noise since the qRT-PCR assay itself is pur-
posed to detect gene expression in very rare populations of 
cells, at a very low and nearly indistinguishable level above 
background. Adaptation of new technologies using sample 
pre-amplification and droplet digital PCR could address this 
current limitation. Alternatively, the heterogeneity observed 
could be biologically meaningful and simply reflect the het-
erogeneity of patients and primary tumors themselves. This 
is further suggested by the fact that when one specific patient 
subpopulation (triple-negative disease) was examined, a 
much more uniform and prognostic pattern of gene expres-
sion was observed. The fact that the eight-gene signature 
identified in the first cohort could be validated, at least in 
part, in a second independent cohort suggests that this pat-
tern of gene expression is more uniform and generalizable 
among triple-negative patients with BM DTCs. However, 
the fact that only five of the originally eight genes chosen 
could provide prognostic accuracy also suggests that further 
studies with additional patients and more sensitive detection 
techniques will be necessary.
In TNBC, pathologic complete response (pCR) after neo-
adjuvant therapy is a significant predictor of survival and 
distant relapse [22, 23]. In this study, gene expression-based 
DTC assessment was performed in BM samples obtained 
prior to any neoadjuvant therapy, purposely to avoid any 
confounding changes in gene expression in the BM due to 
chemotherapeutic effect. Detection and classification of 
DTCs in treatment-naïve patients was comparable to (in the 
first cohort) and superior to (in the second cohort) assess-
ment of primary tumor pCR after neoadjuvant therapy for 
predicting time to distant metastases (p = 0.05 vs. p = 0.03 
in cohort 1; p = 0.02 vs. p = 0.12 in cohort 2, Fisher’s exact 
test). This might be unexpected as therapeutic course could 
greatly influence the residual DTC population and affect 
overall and recurrence-free outcomes, although the TNBC 
patients in this study received fairly uniform neoadjuvant 
and adjuvant therapeutic regimens. Importantly, it is also 
324 Breast Cancer Research and Treatment (2019) 178:317–325
1 3
interesting to note that a positive eight-gene DTC panel 
result, assayed prior to the initiation of any therapy, also cor-
related with primary tumor response to neoadjuvant therapy 
(Fig. 4). In this regard, with respect to TNBC patients, it is 
possible that those same patients with early tumor cell dis-
semination to the BM or very heterogeneous tumors may 
also be those whose primary tumors and DTCs are more 
refractory to conventional chemotherapy. It will be of future 
interest to compare patterns of BM DTC gene expression 
pre- and post-therapy to determine whether changes in gene 
expression are more clinically significant for predicting 
future metastatic spread.
Finally, beyond the potential prognostic utility of this 
gene expression panel, this study demonstrates a possible 
approach to BM-based targeted therapeutics. As previ-
ously reported [20], patients may frequently present with 
ERBB2-negative tumors (who were not treated with Tras-
tuzumab) but with detectable ERBB2-positive gene expres-
sion in their BM, presumably emanating from DTCs. In 
this study, four such patients had a much shorter time to 
distant metastatic relapse as compared to both patients with 
no detectable DTCs and importantly, patients with ERBB2-
positive DTCs who were treated with Trastuzumab because 
their primary tumor was also ERBB2 positive. Several other 
‘DTC-specific’ genes in this panel (PDGFRB, STEAP1, 
SRC, WNT5A, PTCH1), although not necessarily prognos-
tic in this study, could also serve as potential therapeutic 
targets, even if they have proven less effective targets for the 
treatment of primary breast tumors in otherwise unselected 
patient population [24, 25]. Given that the expression of 
these genes is sufficiently specific, we foresee a potential 
to use this panel for the identification of patients who are at 
high risk of distant recurrent disease development despite 
standard-of-care chemotherapy and who may benefit from 
biomarker-directed therapy based on DTC (rather than pri-
mary tumor) gene expression to eradicate BM DTCs and 
mitigate future metastatic relapse in breast cancer patients.
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